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Resumo
Objectivo: O receptor do factor de crescimento epidér-
mico (EGFR) está sobreexpresso na maioria dos carci-
nomas do pulmão de não pequenas células (CPNPC) e 
é um dos principais alvos específicos dos inibidores da 
tirosina cinase (TKI) utilizados para o tratamento do 
CPNPC avançado. Apesar disto, há um considerável 
número de factores biológicos que também estão asso-
ciados à resposta dos EGFR-TKIs. Este estudo teve 
como principal objectivo a pesquisa de mutações somá-
ticas e amplificação do EGFR em casos de carcinoma 
epidermóide do pulmão. Material e métodos: Secções 
Abstract
Purpose: The epidermal growth factor receptor 
(EGFR) is overexpressed in the majority of non-
small-cell lung cancers (NSCLC) and is a major tar-
get specific EGFR tyrosine kinase inhibitors (TKIs) 
developed and used for the treatment of advanced 
NSCLC. A number of biological factors are also as-
sociated with EGFR-TKIs responsiveness. This study 
was focused on EGFR somatic mutations and ampli-
fications in squamous cell lung cancer. Material and 
methods: Representative sections of squamous cell 
carcinoma were selected from 54 surgical specimens 
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representativas de carcinoma epidermóide foram selec-
cionadas de 54 casos em que o tecido estava fixado em 
formal e incluído em parafina, sendo depois submeti-
dos à construção de TMA. A determinação da expres-
são proteica do EGFR foi feita por imunoistoquímica 
(IHQ) (Zymed, laboratórios). A hibridização in situ de 
fluorescência (FISH) foi realizada com a sonda EGFR 
LSI / CEP 7 (Vysis; Abbott Molecular, EUA). O ADN 
genómico foi extraído de 48 casos, amplificado por re-
acção em cadeia da polimerase (PCR) para pesquisa de 
mutações nos exões 19 (deleções) e 21 (mutações pon-
tuais). Todos os casos expressaram positividade para a 
citoqueratina de alto peso molecular e foi observada ne-
gatividade para CK7, CD56 e cromogranina. Resulta-
dos: A sobreexpressão proteica do EGFR foi identifica-
da em 49 casos, pela aplicação do score de Hirsh/
Cappuzzo (2005). A pesquisa de alterações génicas no 
cromossoma 7 e do gene EGFR foram analisadas por 
FISH e de acordo com o método de Cappuzzo (2005), 
foi identificada alta polissomia em 31 casos e amplifica-
ção em 7 casos. Por electroforese capilar, foram detecta-
das no exão 19 do EGFR: deleções em heterozigotia em 
3 dos 48 casos estudados e o exão 21 apresentou-se 
sempre na sua forma wild-type, quando estudado por 
enzimas de restrição. Conclusões: A detecção de dele-
ções e mutações pontuais no EGFR mostrou ser um 
evento raro no carcinoma epidermóide do pulmão. 
Apesar de a presença de mutações no EGFR ser um in-
dicador molecular e de sensibilidade eficaz em doentes 
com CPNPC avançado, submetidos ao tratamento 
com EGFR-TKIs, é a determinação de amplificações e 
de polissomias no gene EGFR que melhor traduz a efi-
cácia do tratamento nos doentes com carcinoma epi-
dermóide, quando isolado do grupo de CPNPC. 
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from formalin-fixed paraffin-embedded tissues and 
submitted to TMA construction. Determination of 
EGFR protein expression was done by immuno-
histochemistry(IHC) (Zymed, Laboratories). Fluo-
rescence in situ hybridization (FISH) was performed 
with LSI EGFR/CEP 7 (Vysis; Abbott Molecular, 
USA). Genomic DNA was extracted from 48 cases 
and exon 19 was amplified by polymerase chain reac-
tion (PCR) for search deletions and point mutations 
for exon 21. All cases expressed high weigh cytokeratin 
and were observed negativity for CK7, CD56 and 
chromogranin. Results: EGFR protein overexpres-
sion was identified in 49 cases, by the application of 
Hirsh’s scoring system. The chromosome 7 and EGFR 
gene were analyzed by FISH and scored according to 
Cappuzzo’s method that showed high polysomy in 31 
cases and amplification in 7 cases. Deletion in exon 
19 of EGFR was detected in 3 cases of 48 samples; 
the exon 21 of EGFR was expressed in its wild type 
by RFLP in all cases. Conclusions: Detection of 
common EGFR deletion and mutation showed to be 
a rare event in Squamous cell carcinoma of the lung. 
While EGFR mutation is the most effective molecu-
lar predictor or sensitivity in patients with advanced 
NSCLC submitted to EGFR-TKIs treatment, ampli-
fication and polysomy is the most effective molecular 
predictor for EGFR-TKIs responsiveness in squamous 
cell carcinoma, when valida ted isolated from the 
group of NSCLC.
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Key-words: Lung cancer, epidermoid carcinoma, 
paraffin-embedded tissue, EGFR, gene amplification, 
gene polysomy.
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Introduction
Lung cancer is one of the most common 
human cancers and the leading cause of 
cancer death world-wide1,2.
Non-small cell lung cancer (NSCLC) com-
prises approximately 85% of all cases divi-
ded into squamous-cell carcinoma (SCC), 
adenocarcinoma (AC), large cells carcino-
mas and others3-5.
The treatment of lung cancer is based on 
the stage of the cancer, and on patients per-
formance status: for patients with early stage 
disease (stage I or II) surgical resection is 
considered the primary therapeutic choice. 
However, that majority of NSCLC cases 
have reached locally advanced (stage III) or 
metastatic stages (stage IV) at the time of 
diagnosis and chemotherapy is usually re-
commended as first line therapy.
Surgical resection is considered to be a cura-
tive treatment during earlier stage disease, 
but 5-year survival after surgical resection 
remains less than optimal, ranging from 
67% for pT1N0 patients to 23% for pa-
tients with ipsilateral mediastinal lymph 
node involvement3-6.
Receptor and non-receptor tyrosine and 
serine/threonine kinases have emerged as 
promising targets for specific drug develop-
ment because overexpression or aberrant 
activation of these kinases often play an im-
portant role in the molecular pathogenesis 
of solid tumours. Further, the structural 
heterogeneity of these kinases has permitted 
development of small compounds which is 
a specific way inhibit their activity.
Epidermal growth factor receptor (EGFR), 
a 170 kDa tyrosine kinase (TK), is a mem-
ber of the human epidermal receptor (HER) 
family that consists of four transmembrane 
tyrosine kinase receptors, EGFR (HER1, 
erbB-1), HER2 (erbB-2, HER/neu), HER3 
and HER4. Upon ligands binding, the re-
ceptors homo or hetero-dimerize in between 
or either other growth factors. Subsequent-
ly, activation of receptor intrinsic tyrosine 
kinase activity occurs together either down-
stream signalling cascades, mainly including 
Ras-Raf-MAP-kinase pathway, PI3K-Akt 
pathway, and STAT pathway. All these have 
strong stimulatory effect on cell prolifera-
tion, differentiation, survival, angiogenesis 
and migration7,8.
EGFR has emerged as a critical tumorigenic 
factor in the development and progression 
of NSCLC. EGFR and erbB-2 are expressed 
in many solid tumours and their overexpres-
sion is associated with poor prognosis.
Activating mutations of EGFR are related to 
increased response rate and survival in pa-
tients treated with EGFR tyrosine kinase in-
hibitors (TKIs)9. Specific EGFR tyrosine ki-
nase inhibitors (TKIs) have been developed 
and used clinically in the treatment of ad-
vanced NSCLC. They disrupt EGFR signal-
ling by competing with adenosine triphos-
phate (ATP) for binding sites at tyrosine 
kinase domain, and thus inhibiting the phos-
phorylation and activation of EGFRs and 
the downstream signalling network10.
Tyrosine kinase inhibitors after first line 
chemotherapy are used to complement con-
ventional chemotherapy and several studies 
are required to define molecular characteris-
tics, different in adenocarcinoma and 
squamous cell carcinoma, to predict the res-
ponse to those drugs11.
Somatic mutation is the mutation that oc-
curs only in somatic cells, which are in con-
trast to germ cells. A large number of so-
matic mutations have been identified in the 
EGFR gene in NSCLC. In general, these 
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mutations can be included into three major 
types: in-frame deletion, insertion, and mis-
sense mutation. Most of these mutations are 
located in the tyrosine kinase coding do-
main (exons 18-21) of the EGFR gene. The 
amino acids 746-750 encoded by exon 19 
and amino acid 858 encoded by exon 21 are 
two mutation hotspots, which accounts for 
over 80% of all the detected mutations12,15.
A considerable number of retrospective 
studies have reported that two activating 
mutations, small in-frame deletion in exon 
19 and substitution of leucine for arginine 
at amino acid 858 in exon 21 (L858R), 
have a striking correlation with EGFR-TKI 
sensivity.
Both activating mutations are able to en-
hance kinase activity of EGFR and the acti-
vation of its downstream signaling, and play 
a pivotal role in supporting NSCLC cell 
survival. When the specific EGFR-TKIs are 
applied, the excessive survival signals that 
cancer cells are “addicted to” are counter-
atcted and a clear apoptosis occurs14.
The present study intended to clarify the sta-
tus of EGFR gene by FISH, PCR and its im-
munohistochemical expression in squamous 
cell carcinoma of the lung.
Material and methods
Sample selection
A cohort of 54 formalin-fixed paraffin-em-
bedded samples, adequate for analysis were 
included in this retrospective study, concern-
ing sections of squamous cell carcinoma se-
lected from surgical specimens. In Table I is 
resumed the age and gender of the patients.
Slides of tumor samples stained with hema-
toxylin-eosin were independently reviewed 
by two pathologists and representative areas 
were marked. Core tissue biopsy speciemens 
(3mm in diameter) in triplicate were ob-
tained from individual paraffin-embedded 
samples (donor blocks) and arranged in a 
new recipient paraffin block (tissue array 
block) using a punch-extractor pen (Histo-
pat, Histopathology, Ltd.). Each tissue array 
block contain 12 specimens, which allowed 
all 162 specimens (triplicate speciemens of 
54 cases) to be contained in 13 array blocks. 
This TMA construction was used for FISH 
and immunohistochemical analysis.
Immumohistochemistry
Three μm sections of TMA were placed on 
coated slides and were allowed to dry over-
night. After deparaffinization and rehydra-
tion, antigen unmasking was performed us-
ing pronase E for 10 minutes. Endogenous 
peroxidase activity was quenched using 15 
minutes incubation in 3% diluted hydrogen 
peroxide (H2O2). For blocking nonspecific 
binding of secondary antibody, Ultra V 
Block (Ultra Vision Kit; TP-015-HL; Lab-
Vision) was applied to the sections and then 
the sections were incubated at room tem-
perature with primary anitbodies against 
EGFR (clone 31G7; Zymed Laboratories) 
at a dilution of 1:20 for 30 minutes. After 
washing with phosphate-buffered saline 
(PBS) the slides were incubated with biotin-
labeled secondary antibody for 30 minutes. 
Primary antibody biding was located in tis-
Table I – Patients characteristics
Female (7) Male (47)
Age (years) median 65,8 66,9
Age (years) range 54-73 48-84
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sues using peroxidase-conjugated streptavi-
din (LabVision). 3,3-diaminobenzidine tet-
rahydrochloride (DAB) was used as the 
chromogen, according to manufacturer’s in-
structions. The slides were counterstained 
with hematoxylin, dehydrated and mount-
ed. In parallel we used known positive and 
negative controls.
IHC staining for EGFR antibody was scored 
according to Hirsch: intensity and percent-
age of cells. The staining was read as follow:
Grade + Score Intensity/positivity
0 <10 + IHC negative
1 50% cells 10-100 1 – Weak Æ IHC low positive
2 75% cells 101-200 2 – Moderate Æ IHC moderate positive
3 >75% cells 201-300 3 – Strong Æ IHC intense positive
Fluorescence in situ hybridization
In situ hybridization is a sensitive method 
that is generally used to detect specific gene 
sequences in tissue sections or cell prepara-
tions by hybridizing the complementary 
strand of a nucleotide probe to the sequence 
of interest.
Dual-color FISH analysis was performed on 
paraffin-embedded tissue blocks on the cas-
es studied, using the Vysis LSI EGFR/CEP 
7 probe assay (Vysis; Abbott Molecular, 
USA). In brief, sections of 4 μm thickness 
from the tissue microarray blocks were used, 
they were baked overnight at 56°C, deparaf-
finized in xylol, rehydrated in 100%, 70% 
ethanol and bidestilled water. Slides were 
then submitted to a pre-treatment in a pres-
sure cooker with 10mM citric acid-triso-
dium salt buffer pH6 for 4 minutes. Washed 
in 2× SSC salts (sodium chloride and so-
dium citrate) pH 7 for 5 minutes at room 
temperature. Slides were immersed for 15 
minutes in proteinase K solution at 37°C, 
they were then rinsed in 2x SSC pH7 for 5 
minutes at room temperature. The slides 
were then dehydrated in 70%, 90% and 
100% ethanol then air dried. Ten microli-
ters of probe mixture were applied on the 
target areas and a 22mmx22mm glass cover-
slip was placed over the probe.
Coverslips were sealed with rubber cement 
and codenatured at 83°C for 5 minutes and 
incubated overnight at 37°C in a humidity 
chamber. Post-hybridization washes in buf-
fer (50% formamide 2x SSC pH7) at 46°C 
and washed with 2x SSC pH7. Slides were 
air-dried in the dark and counterstained 
with DAPI.
Analysis was performed using Nikon Eclipse 
80i and DXM 1200F Workstation equipped 
with Nikon filter set with single-band exi-
tors for rhodamine, fluorescein isothiocya-
nate, DAPI.
Overlapping cells were excluded from ana-
lysis. Two signals were counted as adjacent 
or fused only if they were separated by less 
than one domain.
One hundred spindel cells interphase nuclei 
with strong and well delineated signals were 
examined by two different individuals. A 
split signal in 5% or more of spindle cells 
was required for a result to be classified as 
positive.
DNA preparation and molecular analysis 
of the EGFR gene
Polymerase Chain Reaction (PCR) – is a 
method that allows logarithmic amplifica-
tion of short DNA sequences within a lon-
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ger DNA molecule. Briefly, genomic DNA 
was extracted from serial 5-μm archival pa-
raffin-embeded tissue, containing a repre-
sentative portion of each tumor block, using 
the QIAmp DNA Mini Kit (Qiagen, IZA-
SA, Portugal). One hundred nanograms 
(ng) of DNA were amplified in a 50 μl reac-
tion solution containing 5 μl of 10x buffer 
(Roche, Portugal), 2,5 mM MgCl2, 0,2 μM 
of each complementary primer, 200 μM de-
oxynucleoside triphosphate and 1 unit of 
DNA polymerase (Roche, Portugal). Ampli-
fications were performed using a 5 minutes 
initial denaturation at 95ºC; follwed by 40 
cycles 30 seconds at 95ºC, 1 minute at 60ºC 
1 minute at 72ºC and a 10 minutes of final 
extension at 72ºC. EGFR gene (exons 19 
and 21) mutations were determinated using 
the intron-based primers according to a 
published method6. We performed muta-
tional analysis of exon 19 deletion and 
L858R point mutation of the EGFR gene, 
as previously described7. Briefly, exon 19 de-
letion was determinated by common frag-
ment analysis using PCR with an FAM-la-
beled primer set, and the products were 
electrophoresed on ABI PRISM 3100 (Ap-
plied Biosystems) and all electropherograms 
were reanalysed by visual inspection to check 
for the mutations. The L858R mutation was 
performed using also MJ MiniOpticon (Bio-
Rad), and its products were then detected by 
restriction fragment length polymorphism 
(RFLP) analysis. The restriction enzyme 
MscI was used to digest the TGGCCA se-
quence in the amplicon of the wild-type al-
lele. In contrast, mutant type (L858R) was 
not digested because of the base substitution 
of T to G at the first base of TGGCCA. On 
the other hand, a new FauI restriction site, 
CCCGC, that can be used to distinguish 
L858R mutant allele from wild-type. The 
PCR products were digested with the restric-
tion enzymes MscI and FauI and run on 3% 
agarose gel, and the existence of this muta-
tion was accessed. The Fig. 4 presents the 
predicted gel-electrophoresis patterns for 
PCR-RFLP samples.
Statistical analysis
Statistical analyses of categorical variables 
were performed using bilateral Chi-squared 
tests or Fisher exact test as appropriate. To 
compare percentage of markers expression 
ANOVA test was applied.
Results
Patient characteristics
This study included 47 male and 7 female 
patients with a median age of 66 years. All 
of them had a history of smoking. Stages 
were diagnosed I (52.8%), II (31.6%) and 
III (15.6%) (Table I).
EGFR expression 
by immunohistochemistry
Immunohistochemical EGFR protein overex-
pression was identified in 49 cases, by the ap-
plication of Hirsh’s scoring system (Table II).
Table II – EGFR protein expression detected by IHC in 
squamous cell carcinoma of the lung
Results Immunohistochemistry
IHC + Low Mod Int14 14 17
IHC - 9
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Table III – Comparision of detected EGFR copy number using FISH and IHC in Squamous cell carcinoma of the lung
TNM status Patients EGFR protein expression IMC
EGFR gene expression 
FISH Cappuzzo
N % Positive n (%) Negative n (%) Positive n (%) Negative n (%)
T1NOMx 14 26% 11 (79%) 3 (21%) 7 (50%) 7 (50%)
T1N1Mx 4 7% 4 (100%) 0 4 (100%) 0
T2N0Mx 19 35% 16 (84%) 3 (16%) 16 (84%) 3 (16%)
T2N1Mx 4 7% 4 (199%) 0 1 (25%) 3 (75%)
T2N2Mx 2 4% 1 (50%) 1 (50%) 1 (50%) 1 (50%)
T3N0Mx 8 15% 7 (100%) 1 (50%) 4 (50%) 4 (50%)
T3N1Mx 2 4% 1 (50%) 1 (50%) 2 (100%) 0
T4N0Mx 1 2% 1 (100%) 0 1 (100%) 0
Table IV – EGFR molecular alterations scored according Cappuzzo et al, 2005 criteria
Results
FISH
Disomy Low trisomy High trisomy Low polysomy HighPolysomy
Amplifi cation 
EGFR / CEP 7
IHC + 5 1 1 6 25 7
IHC - 1 1 1 – 6 –
TOTAL 6 2 2 6 31 7
Table V – Relationship between the results obtained in IHC 
and FISH of 54 screened patients
Results FISH NEG FISH POS TOTAL
IHC NEG 3 6 9
IHC LOW POS 8 7 15
IHC MOD POS 4 10 14
IHC INT POS 3 13 16
TOTAL 18: 3 / 15 36: 6 / 30 54
EGFR mutations determinated 
by FISH and PCR
The chromosome 7 and EGFR gene were 
analyzed by FISH and scored according to 
Cappuzzo’s (2005) method that showed in 
31 cases high polysomy and in 7 cases am-
plification (Table III and Fig. 5).
Through capillary electrophoresis, deletion 
in exon 19 of EGFR was detected in 3 cases 
of 48 samples; the exon 21 of EGFR was 
expressed in its wild type by RFLP in all 
cases (Figs. 1-4).
Correlation between EGFR expression 
and EGFR mutations
(Table V).
2 1
45
Wt
Wt/Del 15bp
Wt/Del 18bp
Fig. 1 – Capillary electrophoresis – Exon 19 of EGFR
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Discussion/Conclusions
EGFR mutation screening could be num-
ber one test to provide the most direct and 
valuable information to help clinicians to 
make treatment decision when dealing with 
NSCLC in general1.
Meanwhile somatic mutations of EGFR gene 
are found in about 2-8% of USA non-small-
cell lung cancer patients because of consider-
ing together all histological types of NSCLC.
In the current study – all smokers: exon 19 
deletion was found in 3/48 (6.25%) of Por-
tuguese derived lung epidermoid carcino-
mas and in exon 21 – any L858R mutation 
in the 48 cases studied was identified. In-
frame deletions in exon 19 and in exon 21 
mutations L858R are the EGFR mutations 
most commonly identified and most clearly 
associated with TKI responsiveness.
Low number of EGFR gene copies per cell, 
including disomic and trisomic patterns, 
did not influence the level of protein expres-
sion, whereas a high gene copy number, 
clustered amplification or high polysomy, 
correlated with protein level.
EGFR protein overexpression in all tumours 
with gene amplification is the mechanism for 
overexpression. Balanced disomy for chro-
mosome 7 and EGFR gene while expressing 
high protein expression might be controlled 
by other mechanisms, the complex interac-
tion between gene and protein levels.
Identifying a panel of predictive markers is 
very important for selection of advanced 
NSCLC patients for EGFR-TKI therapy. 
Although several important demographic 
and clinical factors are associated with treat-
ment response, EGFR somatic mutations 
are still the most effective predictor for 
EGFR-TKI sensitivity in lung cancer histo-
logical types.
Fig. 2 – In–frame deletion of exon 19 (del E746-A750): Representative nucleotide se-
quence of the EGFR gene in tumor speciemens, the nucleotide sequence of heterozygous 
in–frame deletions in exon 19 by direct sequencing (double peaks)
5
43
Wt
No PCR amplifi cation
Fig. 3 – RFLP – Exon 21 of EGFR
Fig. 4 – Agarose gel – Exon 21 of EGFR
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Our study is the first that concerning only 
cases of squamous cell carcinoma of the 
lung in surgical stages, after reviewing the 
published medical literature which only in-
cludes cases of non-small-cell lung Cancer 
in advanced stages with higher expressions 
of the parameters here included.
However, the results obtained showed that 
squamous cell lung carcinoma in surgical stag-
es expressed EGFR protein and high polysomy 
of chromosome 7 in 46.3% and amplification 
in 12.9% of the cases. Only in 3 cases we have 
detected deletions in exon 19.
The presence of high polysomy, amplifica-
tion and deletions in exon 19 of EGFR gene 
have implications on tumorigenesis process 
due to his increased enzymatic activity be-
come a TKIs therapeutic target.
These conclusions have to be correlated 
with follow-up of these patients to define 
potential recurrence related with the results 
obtained.
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